Pliant Therapeutics price target raised to $1.70 from $1.50 at Citi

Citi analyst David Lebowitz raised the firm’s price target on Pliant Therapeutics (PLRX) to $1.70 from $1.50 and keeps a Neutral rating on the shares post the Q2 report. The company largely completed its restructuring during the quarter but the path forward bexotegrast remains unclear, the analyst tells investors in a research note.